Immediate Adverse Reaction and SARS-CoV-2 Anti-Spike Receptor Binding Domain IgG of COVID-19 Vaccines Among Health Staffs

IF 1.9 4区医学 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Disaster Medicine and Public Health Preparedness Pub Date : 2024-04-15 DOI:10.1017/dmp.2024.60

Waleed S. Rasheed, Alaa Noori Sarkees

{"title":"Immediate Adverse Reaction and SARS-CoV-2 Anti-Spike Receptor Binding Domain IgG of COVID-19 Vaccines Among Health Staffs","authors":"Waleed S. Rasheed, Alaa Noori Sarkees","doi":"10.1017/dmp.2024.60","DOIUrl":null,"url":null,"abstract":"Objective: To contain the spread of coronavirus disease 2019 (COVID-19), several vaccines have been developed. This study is intended to elucidate the level of anti-severe acute respiratory syndrome coronavirus 2 immunoglobulin G (anti-SARS-CoV-2-IgG) antibodies for COVID-19 vaccines (Pfizer BioNTech [BNT162b2], Oxford/AstraZeneca [ChAdOx1], and Sinopharm [BBIBP-CorV]) among health staff from health facilities in Duhok province, and it explored the immediate adverse reactions of COVID-19 vaccines among participants. Methods: A longitudinal study was conducted from June 1, 2021, to June 30, 2022, and 300 participants were included through simple random sampling. Results: The immune response 1 mo after the second dose was significantly higher than the sustained immune after 5 and 9 mo as results revealed that, in 100% of study samples who had (ChAdOx1) vaccine, their antibody titers exceeded the positivity threshold of 1 AU/m, while 96% for (BNT162b2) and 90% for (BBIBP-CorV) for the first test after 1 mo from the second dose of the COVID-19 vaccine, and these rates were reduced to 94.6% for (ChAdOx1), 97.8% for (BNT162b2), and 81.9% for (BBIBP-CorV) at 5 mo after the second dose, while simultaneously the seropositivity rates were more reduced at 9 mo to 46.5% for (ChAdOx1), 67.5% for (BNT162b2), and 9.20% for (BBIBP-CorV). In terms of adverse reactionsss, fever was reported as the most prevalent after the first dose in 58% for ChAdOx1, 43% for BNT162b2, and 23% for BBIBP-CorV, followed by muscle pain, joint pain, and shoulder pain for both doses. Conclusions: The implications of the findings from this study are that higher and potentially longer antibody responses can be obtained if the BNT162b2 is given as compared with the other 2 vaccines. Moreover, the booster doses of the COVID-19 vaccine are highly recommended because more than 50% of the participants either have become anti-spike protein negative or have a deficient level of anti-spike protein against COVD-19 vaccines.","PeriodicalId":54390,"journal":{"name":"Disaster Medicine and Public Health Preparedness","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Disaster Medicine and Public Health Preparedness","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/dmp.2024.60","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To contain the spread of coronavirus disease 2019 (COVID-19), several vaccines have been developed. This study is intended to elucidate the level of anti-severe acute respiratory syndrome coronavirus 2 immunoglobulin G (anti-SARS-CoV-2-IgG) antibodies for COVID-19 vaccines (Pfizer BioNTech [BNT162b2], Oxford/AstraZeneca [ChAdOx1], and Sinopharm [BBIBP-CorV]) among health staff from health facilities in Duhok province, and it explored the immediate adverse reactions of COVID-19 vaccines among participants. Methods: A longitudinal study was conducted from June 1, 2021, to June 30, 2022, and 300 participants were included through simple random sampling. Results: The immune response 1 mo after the second dose was significantly higher than the sustained immune after 5 and 9 mo as results revealed that, in 100% of study samples who had (ChAdOx1) vaccine, their antibody titers exceeded the positivity threshold of 1 AU/m, while 96% for (BNT162b2) and 90% for (BBIBP-CorV) for the first test after 1 mo from the second dose of the COVID-19 vaccine, and these rates were reduced to 94.6% for (ChAdOx1), 97.8% for (BNT162b2), and 81.9% for (BBIBP-CorV) at 5 mo after the second dose, while simultaneously the seropositivity rates were more reduced at 9 mo to 46.5% for (ChAdOx1), 67.5% for (BNT162b2), and 9.20% for (BBIBP-CorV). In terms of adverse reactionsss, fever was reported as the most prevalent after the first dose in 58% for ChAdOx1, 43% for BNT162b2, and 23% for BBIBP-CorV, followed by muscle pain, joint pain, and shoulder pain for both doses. Conclusions: The implications of the findings from this study are that higher and potentially longer antibody responses can be obtained if the BNT162b2 is given as compared with the other 2 vaccines. Moreover, the booster doses of the COVID-19 vaccine are highly recommended because more than 50% of the participants either have become anti-spike protein negative or have a deficient level of anti-spike protein against COVD-19 vaccines.

查看原文本刊更多论文

医务人员的即刻不良反应和 COVID-19 疫苗的 SARS-CoV-2 抗梭状芽孢杆菌受体结合域 IgG

目的：为遏制 2019 年冠状病毒病（COVID-19）的传播，已开发出多种疫苗。本研究旨在阐明杜霍克省卫生机构医务人员对 COVID-19 疫苗（辉瑞生物技术公司 [BNT162b2]、牛津/阿斯利康公司 [ChAdOx1] 和国药集团 [BBIBP-CorV]）的抗严重急性呼吸系统综合征冠状病毒 2 免疫球蛋白 G（抗 SARS-CoV-2-IgG ）抗体水平，并探讨参与者对 COVID-19 疫苗的直接不良反应。研究方法从 2021 年 6 月 1 日至 2022 年 6 月 30 日进行纵向研究，通过简单随机抽样纳入 300 名参与者。研究结果结果显示，在接种（ChAdOx1）疫苗的研究样本中，其抗体滴度超过阳性阈值1 AU/m的占100%，而在接种第二剂COVID-19疫苗1个月后的首次检测中，（BNT162b2）的抗体滴度超过阳性阈值的占96%，（BBIBP-CorV）的抗体滴度超过阳性阈值的占90%。同时，血清阳性率在接种第二剂疫苗后 9 个月时进一步降低，(ChAdOx1) 为 46.5%，(BNT162b2) 为 67.5%，(BBIBP-CorV) 为 9.20%。在不良反应方面，首次用药后发热的比例最高，ChAdOx1 为 58%，BNT162b2 为 43%，BBIBP-CorV 为 23%，其次是肌肉疼痛、关节疼痛和肩部疼痛。结论本研究结果的意义在于，与其他两种疫苗相比，如果接种 BNT162b2，可获得更高的抗体反应，而且时间可能更长。此外，强烈建议接种 COVID-19 疫苗的加强剂量，因为超过 50% 的参与者已经出现抗尖头蛋白阴性或对 COVD-19 疫苗的抗尖头蛋白水平不足。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Disaster Medicine and Public Health Preparedness PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

4.40

自引率

7.40%

发文量

258

审稿时长

6-12 weeks

期刊介绍： Disaster Medicine and Public Health Preparedness is the first comprehensive and authoritative journal emphasizing public health preparedness and disaster response for all health care and public health professionals globally. The journal seeks to translate science into practice and integrate medical and public health perspectives. With the events of September 11, the subsequent anthrax attacks, the tsunami in Indonesia, hurricane Katrina, SARS and the H1N1 Influenza Pandemic, all health care and public health professionals must be prepared to respond to emergency situations. In support of these pressing public health needs, Disaster Medicine and Public Health Preparedness is committed to the medical and public health communities who are the stewards of the health and security of citizens worldwide.